NCT04132817: A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2-Breast Cancer That Has Spread

NCT04132817
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody, Chemotherapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have 1 – 3 prior regimens for the treatment of metastatic disease, including endocrine therapy or chemotherapy
Exclusions: Patients with prior therapy with anti-PD-1, anti-PD-L1 or anti-CTLA-4 antibody
https://ClinicalTrials.gov/show/NCT04132817

Comments are closed.

Up ↑